ReviewEnvironmental health perspectives2001
An overview of rodent toxicities: liver and kidney effects of fumonisins and Fusarium moniliforme.
Review in Environmental health perspectives, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 171 citations in OpenAlex.
- Curcumin Mitigates Fumonisin BToxins · 2026Article
- Liver Lipidomics, Histology, Transcriptomics, and Clinical Chemistry of Rats Intraperitoneally Treated with Fumonisin B1 for 5 days.Journal of agricultural and food chemistry · 2025Article
- Measurement of hepatic glucose (Scientific reports · 2024Article
- Article
- Review
- Genetic assessment of the effect of red yeast (Frontiers in microbiology · 2023Article
- Investigation of the Genotoxic Potential of the Marine Toxin C17-SAMT Using the In Vivo Comet and Micronucleus Assays.Marine drugs · 2022Article
- Article
- Mycotoxin Fumonisin BToxins · 2021Article
- The Future of Antifungal Drug Therapy: Novel Compounds and Targets.Antimicrobial agents and chemotherapy · 2021Review
- Fungal sphingolipids: role in the regulation of virulence and potential as targets for future antifungal therapies.Expert review of anti-infective therapy · 2020Review
- Esophageal cancer in Mozambique: should mycotoxins be a concern?The Pan African medical journal · 2019Article
- Review
- Appropriateness to set a group health-based guidance value for fumonisins and their modified forms.EFSA journal. European Food Safety Authority · 2018Article
- Review
- Factors associated with the high prevalence of oesophageal cancer in Western Kenya: a review.Infectious agents and cancer · 2017Review
- Prevalence of aflatoxin and fumonisins (BToxicology reports · 2016Article
- 1-Deoxysphingolipids Encountered Exogenously and Made de Novo: Dangerous Mysteries inside an Enigma.The Journal of biological chemistry · 2015Review
- In vivo formation of N-acyl-fumonisin B1.Mycotoxin research · 2015Article
- Toxicity evaluation of microemulsion (nano size) of sour cherry kernel extract for the oral bioavailability enhancement.Jundishapur journal of natural pharmaceutical products · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fumonisins are produced by Fusarium moniliforme F. verticillioides) and other Fusarium that grow on corn worldwide. They cause fatal toxicoses of horses and swine. Their effects in humans are unclear, but epidemiologic evidence suggests that consumption of fumonisin-contaminated corn contributes to human esophageal cancer in southern Africa and China. Much has been learned from rodent studies about fumonisin B1(FB1), the most common homologue. FB1 is poorly absorbed and rapidly eliminated in feces. Minor amounts are retained in liver and kidneys. Unlike other mycotoxins, fumonisins cause the same liver cancer promotion and subchronic (studies (3/4) 90 days) liver and kidney effects as (italic)F. moniliforme. FB 1 induces apoptosis of hepatocytes and of proximal tubule epithelial cells. More advanced lesions in both organs are characterized by simultaneous cell loss (apoptosis and necrosis) and proliferation (mitosis). Microscopic and other findings suggest that an imbalance between cell loss and replacement develops, a condition favorable for carcinogenesis. On the molecular level, fumonisins inhibit ceramide synthase, and disrupt sphingolipid metabolism and, theoretically, sphingolipid-mediated regulatory processes that influence apoptosis and mitosis. Liver sphingolipid effects and toxicity are correlated, and ceramide synthase inhibition occurs in liver and kidney at doses below their respective no-observed-effect levels. FB1 does not cross the placenta and is not teratogenic in vivoin rats, mice, or rabbits, but is embryotoxic at high, maternally toxic doses. These data have contributed to preliminary risk evaluation and to protocol development for carcinogenicity and chronic toxicity studies of FB1 in rats and mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.